E., Dalhoff, K
Formulated to address nutrient gaps linked with GLP-1 appetite reduction
47 The doses of semaglutide available for subcutaneous injection are 0.25 mg, 0.5 mg, 1 mg, or 2 mg for type 2 diabetes, and 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg for obesity, respectively
Neurological Research , 23 (7)
How to Safely Use GLP-1 Medications for Metabolic Support GLP-1 medications work in part by dramatically slowing gastric emptying: essentially, they make your stomach take longer to process food and medications
While these methods can be helpful for some, they often require strict adherence to diet and exercise with limited success in individuals who struggle with metabolic disorders, insulin resistance, or hormonal imbalances